DIOS CoVax2
Alternative Names: COVID -2019 vaccine - DIOSynVax; DIOS-CoVax2; pEVAC-PSLatest Information Update: 20 Dec 2021
At a glance
- Originator DIOSynVax
- Class COVID-19 vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 14 Dec 2021 Phase-I clinical trials in COVID-2019 infections (Prevention) in United Kingdom (Intradermal) (ISRCTN87813400)
- 30 Oct 2020 DIOSynVax plans a phase I trial for Covid-2019 infections (DIOSynVax website October 2020)
- 28 Oct 2020 Early research in COVID-2019 infections in United Kingdom (Prevention) (Intradermal)